Recombinant Human FLJ10719 Protein

Recombinant human FLJ10719 protein is a genetically engineered form of the naturally occurring FLJ10719 protein encoded by the human C12orf10 gene (chromosome 12 open reading frame 10). Although its biological functions remain incompletely characterized, FLJ10719 is predicted to play roles in cellular processes such as protein binding, signal transduction, or regulation of metabolic pathways based on sequence homology and limited experimental studies. The protein contains conserved structural domains, including potential transmembrane regions and phosphorylation sites, suggesting involvement in membrane-associated activities or post-translational modifications.

Recombinant FLJ10719 is typically produced in heterologous expression systems like E. coli or mammalian cell lines, enabling controlled production for research applications. Purification tags (e.g., His-tag) are often incorporated to facilitate isolation. This engineered approach allows researchers to study FLJ10719’s biochemical properties, interactome, and potential roles in diseases. Preliminary evidence links FLJ10719 to cancer progression, neurological disorders, and immune responses, though mechanistic insights are scarce. Its expression patterns in specific tissues and differential regulation under pathological conditions have prompted interest in its biomarker potential or therapeutic targeting. Current research focuses on elucidating its 3D structure, binding partners (e.g., reported interactions with CCT complex proteins), and functional validation using knock-out models. The recombinant protein serves as a critical tool for antibody development, enzymatic assays, and pathway analysis, bridging gaps between genomic data and functional proteomics.